Arterial Occlusive Diseases Clinical Trial
Official title:
The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery: Possibility of Risk Assessment and Stratification
The aim of the present study is the evaluation of cardiovascular biomarkers in patients with
abdominal aortic aneurysms (AAA) or abdominal aortic occlusive disease AOD) undergoing open
(OR) or endovascular aortic repair (EVAR) with regards to short- and long-term outcome.
By blood collection and measurement of the serum biomarkers Copeptin, N-terminal- pro Brain
Natriuretic Peptide (NT-proBNP), cardiac Troponin I (cTnI), high sensitive Troponin T
(hs-cTnT) and C-reactive Protein (CRP) we expect an improvement of patients stratification
by assessment of cardiac stress tolerance. Data gathered may help to simplify the decision
whether an open or endovascular approach for abdominal aortic repair (OR and EVAR) should be
performed.
Study Hypothesis:
The evaluation of the predictive value of cardiovascular biomarkers (Copeptin, NT-proBNP,
hsTnT, cTnI, CRP) improve patient stratification and selection of surgical treatment.
Background:
The prevalence of coronary artery disease (CAD) in patients with aneurysmal or occlusive
disease of the aorta is high: more than 50 percent of patients suffering from peripheral
arterial occlusive disease (PAOD) or abdominal aortic aneurysm (AAA) do also have coronary
artery disease. As a result, cardiovascular disease is the leading cause of morbidity and
mortality in patients undergoing aortic surgery.
Identifying patients at increased risk of cardiac complications following major vascular
surgery is also part of the decision-finding process when patients are assigned to open or
endovascular surgery. The 30-day mortality rate for elective open aneurysm repair (OR) is
estimated to be 4 to 8%, while endovascular aneurysm repair (EVAR) has a perioperative risk
of 1.2 to 1.6%. However, the early survival advantage of patients undergoing EVAR disappears
with time and all-cause mortality is similar for EVAR and open repair at late follow-up.
Patients treated by EVAR show a higher number of complications and reinterventions, and a
significant proportion of late deaths after EVAR are due to aneurysm rupture.
Therefore, patients who need abdominal aortic surgery are required to undergo a thorough
medical examination, on the one hand to assess cardiac capacity, on the other hand to
estimate life expectancy. Current recommendations for the preoperative management of
patients undergoing major non-cardiac vascular surgery include physical examination and
routine performance of electrocardiogram and echocardiogram as part of a cardiovascular
evaluation. However, guidelines do not include routine screening with cardiac enzymes or
cardiac stress markers.
Biomarkers:
Brain natriuretic peptide (BNP) and the inactive precursor N-terminal prohormone of brain
natriuretic peptide (NT-proBNP) are valuable screening tools for identifying patients who
may suffer from heart failure. NT-proBNP plays an important role in heart remodeling and
volume homeostasis. It is an important indicator of prognosis in heart failure and after
acute myocardial infarction. Elevated pre- and postoperative plasma NT-proBNP levels
independently predict postoperative myocardial injury, which is associated with adverse
outcome in the short- and long-term regardless of the presence of symptoms of acute coronary
syndrome.
Copeptin is a novel marker that allows highly sensitive but unspecific assessment of stress.
Copeptin is the C-terminal fragment of provasopressin, the precursor peptide of vasopressin
(antidiuretic hormone). Vasopressin is released by the neurohypophysis in order to promote
water absorption and vasoconstriction, and thereby contributes to osmotic and cardiovascular
homeostasis. Due to the fact that Vasopressin is unstable in the peripheral circulation, the
stable Copeptin, which is released in equimolar amounts, is measured instead of Vasopressin.
Recent studies have shown that this peptide may also be applied for the assessment of the
risk of morbidity and mortality: increased copeptin levels are associated with poor short-
and long- term prognosis after myocardial infarction and stroke.
Troponins are widely used biomarkers for the diagnosis and management of acute myocardial
infarction and acute coronary syndrome. Troponin is an essential protein of muscle cells.
Thus, damage to the heart muscle, such as coronary vasospasm, cardiomyopathy, heart failure
and myocarditis, can be indicated by elevated serum levels of cardiac troponin. The most
common cause of raised troponins is myocardial ischemia as a result of acute coronary
syndrome or myocardial infarction. In patients undergoing major vascular surgery even early
small postoperative rises in troponin have been shown to correlate with adverse short- and
medium-term outcome.
C-reactive protein (CRP), an acute-phase protein, is a sensitive marker of inflammation and
tissue damage. Elevated CRP levels are able to predict future atherothrombotic events, such
as stroke, coronary events and progression of peripheral arterial disease. Furthermore,
inflammation is crucially involved in atherosclerosis and plaque development.
Material and Methods:
Study Design Prospective, non-randomized, open-labeled, observational study
Patient Population:
500 patients of the Department of Vascular and Endovascular Surgery of the
Wilhelminenhospital (Vienna). Preoperative evaluation includes electrocardiography,
echocardiography and internal medical examination. Comorbidities, history of cardiac events,
previous operations, routine laboratory tests and current medication are documented.
Blood Sampling and Laboratory Measurements:
Blood samples are obtained by venipuncture and collected in standard serum and EDTA tubes
preoperatively, 48 hours postoperatively, ten days and six weeks after surgery, centrifuged
for 20 minutes at 2000 G and the plasma is stored in aliquots at minus 80 degrees Celsius
until determination of the respective biomarkers.
Surgical procedures:
Surgery is standardized by performing endovascular aortic repair (EVAR) or open surgical
procedures (OR). OR is performed in general anesthesia via a transabdominal or
retroperitoneal approach that allows repair of the aneurysmal or stenosed aorta with tube-
or bifurcated grafts. In contrast, groin access for EVAR is achieved in local anesthesia.
Statistical Analysis:
The study cohort consists of three study groups: patients with AAA undergoing EVAR, patients
with AAA undergoing OR and patients suffering from AOD undergoing open surgical repair. All
patients will be observed until complete follow-up (plasma samples at 0, 2 days, 10 days, 6
weeks and an annual outpatient checkup thereafter) or until a primary fatal outcome event.
The statistical distribution of the serum levels of the respective biomarkers is assessed by
a histogram. The skewed distribution prompts non-parametric tests (Mann-Whitney-U) for
comparison of medians by (gender and status of survival). The effect of biomarkers on 5-year
postoperative survival (primary endpoint) is estimated in uni- and multivariate proportional
hazard models (Cox Regression) for establishment of a prognostic model. In order to adjust
for confounders, the latter includes classic cardiovascular risk factors (age, hypertension,
nicotine abuse, diabetes mellitus, history of cardiac events, high lipoproteins), which are
documented preoperatively and entered as covariates. Survival estimates stratified by the
three study groups will be shown in Kaplan Meier Curves (log-rank test). A two-sided p-value
(P) of less than 0.05 is considered to indicate statistical significance. Hosmer and
Lemeshow tests are performed to test for adequacy for all regression models (P > 0.05).
Tests for proportional hazard assumption is performed through linear regression of partial
residuals (Schoenfeld) for each variable and 5-year survival time. Cox proportional hazards
model are presented as hazard ratio (HR) and 95% confidence interval (CI). All statistical
analyses are performed with the use of SPSS 20 (IBM Inc., Somers, NY 10589, USA.).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03724279 -
Crossing Atheroma or Thrombus With ByCross Device for Revascularization of Peripheral Arteries of Diameter ≥ 3mm
|
N/A | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Not yet recruiting |
NCT02841488 -
Ischemic Pain Control With Analgesic Methods Clinical Trial
|
Phase 3 | |
Completed |
NCT00371371 -
Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)
|
Phase 1/Phase 2 | |
Completed |
NCT00209443 -
A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide
|
Phase 3 | |
Completed |
NCT00174759 -
CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease
|
Phase 3 | |
Completed |
NCT00000539 -
Arterial Disease Multifactorial Intervention Trial (ADMIT)
|
Phase 3 | |
Recruiting |
NCT04089943 -
The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD
|
N/A | |
Recruiting |
NCT04343209 -
Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
|
||
Not yet recruiting |
NCT05930145 -
Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT04142021 -
Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
|
||
Completed |
NCT03253692 -
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
|
||
Active, not recruiting |
NCT04624854 -
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
|
Phase 4 | |
Active, not recruiting |
NCT02921230 -
Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery
|
N/A | |
Recruiting |
NCT02593994 -
IRIS-Onyx Cohort in the IRIS-DES Registry
|
||
Completed |
NCT02008097 -
Clinical Benefits of B-Flow Ultrasound
|
N/A | |
Terminated |
NCT01462721 -
The eSVS® Mesh Randomized Post-Market Study
|
N/A | |
Completed |
NCT00282646 -
Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)
|
Phase 2 | |
Not yet recruiting |
NCT04956523 -
Preliminary Tissue Monitoring During Endovascular Intervention Study
|
||
Recruiting |
NCT05616104 -
FLEX FIRST Registry Research Protocol
|